Shiba inu who inspired'doge' meme is seriously ill with leukemia | Business
Kabosu, the internet-famous dog who inspired the “doge” meme and influenced digital culture for a decade, is seriously ill with leukemia and liver disease. The 17-year-old shiba inu stopped “eating and drinking voluntarily” on Christmas Eve, and has been diagnosed with acute cholangiohepatitis and…#sans #sato #elonmusk #oreo #kabosu #sakura #dogecoin #proukrainian #atsukosato #tumblr (Source: Reuters: Health)
Source: Reuters: Health - December 28, 2022 Category: Consumer Health News Source Type: news
Patient - Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 22, 2022 Category: Cancer & Oncology Tags: Oncology, Geriatrics, Journal, Source Type: news
Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
THURSDAY, Dec. 22, 2022 -- Incorporation of an innovative patient-centered communication tool (UR-GOAL tool) is feasible for older adults with newly diagnosed acute myeloid leukemia (AML), according to study published online Dec. 19 in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2022 Category: Pharmaceuticals Source Type: news
Single - Tube Multiparametric Flow Cytometry Predicts Treatment Response in Leukemia
Multiparametric flow cytometry has excellent prediction for survival among patients with B - cell acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news
Single-Tube Multiparametric Flow Cytometry Predicts Treatment Response in Leukemia
WEDNESDAY, Dec. 21, 2022 -- A single-tube eight-color multiparametric flow cytometry (MFC) panel has good sensitivity for minimal/measurable residual disease (MRD) and excellent prediction for survival among patients with B-cell acute lymphoblastic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2022 Category: Pharmaceuticals Source Type: news
Immuneel's CAR-T cell therapy reports positive in early phase-2 trials in India
The early results from the IMAGINE study were based on the first 10 patients of the planned 24 patients to be enrolled.Both adult and children with acute leukemia as well as lymphoma patients post median 2 lines of treatment, including in post-transplant settings were enrolled. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 20, 2022 Category: Pharmaceuticals Source Type: news
Mayo Clinic Q & amp;A podcast: Advancing treatments for acute myeloid leukemia
Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease progresses rapidly, affecting a group of white blood cells called myeloid cells, which normally develop into mature red blood cells, white blood cells and platelets. "There are acute and chronic leukemias, explains Dr. James Foran, an oncologist at Mayo Clinic. "The chronic ones tend to happen… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 20, 2022 Category: Databases & Libraries Source Type: news
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib), which is indicated for... (Source: McKesson News)
Source: McKesson News - December 19, 2022 Category: Information Technology Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
' Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT'Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT
Investigators said they were astonished by the results they saw when patients with refractory acute myeloid leukemia went straight to an allogeneic stem cell transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Worldwide Efforts Needed to Close Regional HSCT Utilization Gap Worldwide Efforts Needed to Close Regional HSCT Utilization Gap
Although hematopoietic stem cell transplants (HSCT) offer a cure for acute myeloid leukemia, in some countries only 5% of patients are offered this option.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Neurologic Symptoms Linked With Death in Pediatric Leukemia Neurologic Symptoms Linked With Death in Pediatric Leukemia
Neurologic manifestations such as headache, neuropathy, seizures, and cell infiltration are common in pediatric patients with acute leukemia and are associated with a higher mortality rate, data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
